STATEMENT BY APPLICANT PTO - 1449 FORM

ATTY. DOCKET NO.	SERIAL NO.				
11245/46405	10/661,881				
APPLICANT WAKSAL et al.	·				
FILING DATE	GROUP				
September 11, 2003	1642				

U. S. PATENT DOCUMENTS

		O. D. TATLETT DOG	OTTABLE			
EXAMINE R INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE
/ALH/	4,863,902	September 5, 1989	Amagase et al.			

FOREIGN PATENT DOCUMENTS

			TORLIGHTATION	COMBINE				
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
٠	/ALH/	EP 332 424	March 25, 1992					

OTHER DOCUMENTS

OTHER DOCUMENTS							
EXAMINER INITIAL	-AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.						
/ALH/	Bonner, J.A., et al., "The Interaction of Epidermal Growth Factor and Radiation in Human Head and Neck Squamous Cell Carcinoma Cell Lines With Vastly Different Radiosensitivities", Int. J. Radiation Oncology Biol. Phys., Vol. 29 No. 2, pp.243-247, 1994						
	Huang, S., et al., ABSTRACT in Proceedings of the American Association for Cancer Research Vol. 39, March 1998						
	Huang, SM, et al., "Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck ¹ ", Cancer Research, Vc 59, pp. 1935-1940 April 15, 1999						
	Messa, C., et al., "EGF, TGF-α and EGF-R in Human Colorectal Adenocarcinoma", Acta Oncologica, Vol. 37, No. 3, pp. 285-289, 1998						
·	Real, F.X., "Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation ¹ ", Cancer Research Vol. 46, pp. 4726-4731, September 1986						
	Masui, H., et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Moloclonal Antibodies1", Cancer Research Vol. 44, pp. 1002-1007, March 1984						
	Goldstein, N.I., et al., "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", Clinical Cancer Research, Vol. 1, pp. 1311-1318, November 1995						
	Wells, W., et al., "EGF Receptor and p185 ^{erbB-2} -Specific Single-Chain Antibody Toxins Differ in Their Cell-Killing Activity on Tumor Cells Expressing Both Receptor Proteins" Int. J. Cancer, Vol. 60, pp. 137-144, 1995						
	Moyer, J.D., "Induction of Apoptosis and Cell Cycle Arrest by CP-358, 774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Research Vol. 57, pp. 4838-4848, November 1, 1997						
	Prewett, M., "The biologic Effects of C225, A Chimeric Monoclonal antibody to the EGFR, on Human Prostate Carcinoma", Journal of Immunotherapy, Vol. 19, No. 6, pp. 419-427, 1997						
	Baselga, J., and Mendelsohn, J., "The epidermal growth factor receptor as a target for the therapy in breast carcinoma", Breast Cancer Research and Treatment, Vol. 29, pp. 127-138, 1994						
V	Baselga, J., et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal antibodies", Journal of the National Cancer Institute, Vol. 85, No. 16, August 18, 1993						

DATE CONSIDERED							
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED CENTRAL FAX CENTER

P. 03

JUN 2 6 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM			ATTY. DOCKET NO. 11245/46405 APPLICANT WAKSAL et al. FILING DATE September 11, 2003			11	SERIAL NO. 10/661,881 GROUP 1642			
		U. S. PA	TENT DOC	UMENTS					. 1 ==	
EXAMINE R INITIAL	EXAMINE PATENT PATEN R NUMBER DATE		TT :	NAME	NAME		CLASS SUBO			LING ATE
/ALH/	6,217,866	Ap	nil 17, 2001	Schlessinger				<u> </u>		
		FOREIG	N PATENT DO	CUMENTS						ATION
EXAMINER INITIAL	DOCUMENT DATE NUMBER			COUNTRY CLASS		S SUBCLASS		CLASS	TRANSLATION YES NO	
	·					\dashv				
EXAMINER INITIAL		<u>თ</u>	THER DOCUM	ents E. Date, Pertiner	NT PAGES	s, etc		,		
				<u> </u>						
										

		DATE CONSIDERED
EXAMINER	/Anne Holleran/ (03/19/2007)	
	itial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw	line through citation if not in conformance and
EXAMINER: I	nitial if citation considered, whether or not citation is in conformance with this . 2.1. 00%, citation	11110 0110-01
	believe some of this form with next communication to applicant.	